Form 4 for NMRA Neumora Therapeutics, Inc.
Accepted 2025-02-20 00:00:00 ET · period of report 2025-02-18 · accession 0001610717-25-000029 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2025-02-20 | 2025-02-18 | NMRA | Aurora Daljit Singh | Chief Strategy Off | S - Sale | $1.68 | -8,565 | 88.9K | -9% | -$14.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-18 | S | D | 8,565 | $1.68 | 88,935 | D | — | — | (F2) This transaction was executed in multiple trades in prices ranging from $1.66 to $1.705, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |